AUTHORS
Axelle Kern, PhD, MSc, Catherine Bourdon2, Pierre Mangin, PhD3, Alexandra Yakusheva4
AFFILIATIONS
1 INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France
2 INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France
3 INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France
4 INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France, ThrombInnov, Strasbourg, France
ABSTRACT
Rupture of an atherosclerotic plaque initiates thrombus formation, which can result in acute cardiovascular events such as myocardial infarction and ischemic stroke. Stent implantation is the standard therapeutic intervention for restoring blood flow and preventing distal embolization. However, its clinical efficacy is limited by the risk of stent thrombosis (ST), a serious complication associated with significant morbidity and mortality. This is notably evident in tandem lesion patients in which the incidence of stent thrombosis exceeds 20% remaining a unmet medical need. We developed complementary in vitro and in vivo models of carotid ST to investigate its underlying mechanisms and identify safer antithrombotic strategies.
In vitro, stent thrombosis was assessed by perfusing hirudinated human whole blood through on-scale macrofluidic flow chambers mimicking the human carotid artery coated with human atherosclerotic plaque homogenates (HAPH) and implanted with a stent used in clinic. In vivo, ST was evaluated by intravital microscopy and Doppler probe measurements after implantation of a stainless-steel stent into the carotid artery of wild-type or hGPVI mice pretreated with antiplatelet inhibitors.
In the macrofluidic model, real-time video-microscopy showed that blood perfusion trough a carotid stented macrofluidic chamber coated with HAPH resulted in the formation of very large thrombformation, both on the stented surface containing plaque material, and in the bifurcation devoid of thrombogenic plaque. Scanning electron microscopy showed that the platelets within the thrombi were highly activated, as evidenced by shape change with filopodia extension. Aspirin showed a significant reduction in thrombus formation (90 % inhibition, p ≤ 0.01). Moreover, treating blood with glenzocimab (50μg/mL), an anti-GPVI agent, efficiently prevented platelet accumulation (82 % inhibition, p ≤ 0.01), suggesting that GPVI plays an important role in this innovative experimental model of acute ST.
In vivo, the surgical procedure combined to carotid stent implantation consistently induced occlusive fibrin-rich thrombosis. Aspirin reduced thrombus area and decreased the incidence of occlusive thrombosis by 37.5%. Fibrin deposition was significantly lower in non-occlusive thrombi compared to occlusive thrombi in aspirin-treated mice (p ≤ 0.01), suggesting that fibrin accumulation is associated with vessel occlusion. Consistent with this, inhibition of platelet αIIbβ3 with GR144053 (5 mg/kg), either alone or combined with aspirin, completely prevented occlusive thrombosis and abolished fibrin accumulation. Finally, GPVI inhibition with glenzocimab (8 mg/kg) prevented occlusive thrombus formation and reduced thrombus area in aspirin-treated hGPVI mice.
In conclusion, we developed in vitro and in vivo models that reproduce key features of carotid stent thrombosis and provide robust platforms for mechanistic and pharmacological studies. Our findings support critical roles for platelet GPVI in carotid stent thrombosis and provide a rationale for their further evaluation as therapeutic targets to prevent ST.
DISCLOSURES
Alexandra Yakusheva: ThrombInnov - Current equity holder in private company; ThrombInnov - Current Employment